Menu
Born 1974. Chairman of the Board since November 2014.
Education & experience
BSc from the London School of Economics. Henrik Rammer has been Chair of the Board of Directors for all companies in the Chordate Group since November 2014. Henrik has many years of experience in private equity and has worked at Axcel Management AB from 2008 to 2013 and at Triton Advisers (Sweden) AB from 2002 to 2007. Today, Henrik works as a private investor in a number of other companies. Henrik has also been a director of the following companies: Scandinavian Cosmetic Group Holding AB, Sveriges godaste matmarknad AB, Sensa Bues AB and Axcel Management AB.
Other current assignments
Director of AddBIO AB, MYoroface AB, SnowSail Invest AB, RRM Sponsor AB, Rammer Holding AB and Chair of the Board of Directors of RRMC AB and an Alternate Director of RRM Nordic Financial Services Acquisitions AB and Homekey AB.
Shares: 6,664,798
Warrants: 350,000 of series 2023/2025:2
Born 1961. Vice Chairman of the Board since May 2023
Education & experience
A master’s degree in chemical engineering from KTH Royal Institute of Technology in Stockholm. Otto Skolling has over 30 years of experience in product development, business development and project management within the pharmaceutical and medical technology industry, and he has previously held leading positions at, among others, Novozymes, Siemens Life Support Systems, Pharmacia & Upjohn. Otto has also been the chair of the Board of Directors of Volusense AS and a Board member of Asarina Pharma AB, Bactaviva AB, Nanexa AB and Athera Biotechnologies AB.
Other current assignments
Otto is today chief business officer of Asarina Pharma AB, a Board member of Isles of Wines AB, Respinor AB (publ) and Lipidor AB and chair of the Board of Pharmor AB. He is also responsible for business development for Nanexa AB and Dilafor AB
Shares: 0
Warrants: 350,000 of series 2023/2025:2
Born 1955. Board member since June 2014.
Education & experience
Chemical Engineering degree course followed by a tertiary education in economics. Tommy was CEO of Atos Medical from 1998 to 2014 and was a Member of its Board of Directors from 2014 to 2016. He has also worked with sales and marketing at Atos Medical, where he started in 1990. Before Tommy started working at Atos Medical, he worked with sales and marketing at Medscand AB and Janssen Pharma AB. Tommy has previously been a Board member of Carponovum, M-V Arterica AB and Cross Technology Solutions AB.
Other current assignments
Tommy currently has a number of other directorships in the life sciences sector. Member and Chair of the Board of Directors of Lindhe Xtend AB and Askis AB. Member of Avidicare Holding AB, Cross Technology Solutions AB and Neola Medical AB (Publ.) CarpoNovum AB.
Shares: (and through related parties) 12,399,852
Warrants: 225,000 of series 2023/2025:2
Born 1963. Board member since April 2017.
Education & experience
Med. BSc and Executive MBA from Uppsala University. Gunilla is currently CEO of Uppsala University Invest AB, she has held leading positions in the life sciences sector for more than 25 years. Most recently, Gunilla was CEO of Pharmanest AB, where she led development from concept phase to commercialization. Prior to that, Gunilla was Deputy CEO of Q-Med AB. Gunilla has also been a Board member in Linnéa Capital I AB, Strike Pharma AB, Uppsala-Gruppen Utbildning & Organization AB, Addbio AB and ExScale Biospecimen Solutions AB.
Other current assignments
Among other posts, Gunilla is a Board member of CombiGene AB, IPF – institutet för Personal och Företagsutveckling AB, Uppsala Universitets Projekt AB, Uppsala Innovation Centre AB, Lipidor AB, Uppsala Universitet Research Intellectual Property AB and Samplefacts AB.
Shares: 0
Warrants: 350,000 of series 2023/2025:2
Born 1979. Board member since October 2021.
Education & experience
MSc in Engineering Physics with an MSc from Uppsala University and an Executive MBA from Stockholm University. Caroline is a certified Board Member, Styrelseakademien. Caroline is currently Global Sales Director at the climate technology company Deedster, and has previously worked at Ericsson, among others, in various leading roles with a focus on sales and marketing. Caroline has previously been a Board member of Viddget Holding AB. She also has a number of different directorships and advisory board roles, including at Stockholm University.
Other current assignments
Caroline is a deputy Board member of Just Management.
Shares: (and through related parties) 19,043,519
Warrants: 350,000 of series 2023/2025:2
Öhrlings PricewaterhouseCoopers with authorized public accountant Henrik Boman as principal auditor.
We are a Swedish medical technology company listed on Nasdaq First North Growth Market.
Chordate has spent more than 10 years developing the treatment Ozilia®, which is based on Kinetic Oscillation Stimulation, a technique for treating chronic migraine and chronic rhinitis. We have a patent on Ozilia® in the EU and the United States, as well as many other countries.
We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH).
The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.